Posttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: Should we keep track?
![Thumbnail](/bitstream/handle/20.500.14178/2140/Letter_Am%20J%20Hematol_2023_preprint_%2barticle.pdf.jpg?sequence=5&isAllowed=y)
Autor
Datum vydání
2023Publikováno v
American Journal of HematologyRočník / Číslo vydání
98 (10)ISBN / ISSN
ISSN: 0361-8609ISBN / ISSN
eISSN: 1096-8652Metadata
Zobrazit celý záznamKolekce
Tato publikace má vydavatelskou verzi s DOI 10.1002/ajh.27022
Abstrakt
Klíčová slova
Trvalý odkaz
https://hdl.handle.net/20.500.14178/2140Licence
This is the peer reviewed version of the following article: [Zuna J, Hovorkova L, Zaliova M. Posttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: Should we keep track? Am J Hematol. 2023 Oct;98(10):E269-E271. Jul 14. PMID: 37449465.], which has been published in final form at [https://doi.org/10.1002/ajh.27022]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.